Loading...
Loading...
CKPT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 8.3M |
| Gross Profit | -8.3M |
| Operating Expense | 10.2M |
| Operating I/L | -10.2M |
| Other Income/Expense | -9.0M |
| Interest Income | 0.0M |
| Pretax | -19.1M |
| Income Tax Expense | 15.3M |
| Net Income/Loss | -19.1M |
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company specializing in acquiring, developing, and commercializing novel treatments for solid tumor cancers. The company's lead products include Cosibelimab, a monoclonal antibody that blocks PD-L1 interaction, CK-302, a human agonistic antibody designed to trigger signaling in GITR expressing cells, Olafertinib for EGFR mutation-positive non-small cell lung cancer, CK-103, a small molecule inhibitor, and an anti-CAIX antibody for recognizing and killing CAIX expressing cells. Checkpoint Therapeutics generates revenue through the development and commercialization of these innovative treatments for cancer patients.
